BMS-986497 (ORM-6151)

Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
35 patients (estimated)
Sponsors
Bristol Myers Squibb
Tags
GSPT1 Degrader, CD33
Trial Type
Treatment
Last Update
3 months ago
SparkCures ID
1914
NCT Identifier
NCT06419634

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.